Revagenix is a preclinical-stage biopharmaceutical company dedicated to the discovery and development of life-changing and life-saving medicines for underserved patients. The company is advancing its portfolio of novel antibiotics, leveraging innovative and proprietary chemistry capabilities to design therapeutics to treat infections caused by multidrug-resistant organisms.

Revagenix’s lead program is a best-in-class, broad-spectrum antibiotic to treat infections caused by multidrug- and pan-resistant bacterial strains including WHO critical- and high-priority pathogens such as Enterobacteriaceae, P. aeruginosa, A. baumannii, and S. aureus. The company’s pipeline includes broad-spectrum agents with novel mode of action.

Founded by industry veterans, Revagenix is committed to thought leadership and engagement across industry, investors, agencies, regulators, and policymakers, contributing to the development of holistic solutions to address the antibiotics commercial landscape.